- Differential Diagnosis
Drug Information for FLUOXETINE TABLETS USP, 10 mg7188Rx only (Teva Pharmaceuticals USA): CONTRAINDICATIONS
- ADVERSE REACTIONS
- HOW SUPPLIED
- ANIMAL TOXICOLOGY
- MEDICATION GUIDE
- Diseases/Conditions Related to FLUOXETINE TABLETS USP, 10 mg7188Rx only (Teva Pharmaceuticals USA)
- External Links Related to FLUOXETINE TABLETS USP, 10 mg7188Rx only (Teva Pharmaceuticals USA)
Fluoxetine hydrochloride is contraindicated in patients known to be hypersensitive to it.
Monoamine Oxidase Inhibitors
There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI. Since fluoxetine and its major metabolite have very long elimination half-lives, at least 5 weeks [perhaps longer, especially if fluoxetine has been prescribed chronically and/or at higher doses (see CLINICAL PHARMACOLOGY, Accumulationand slow elimination)] should be allowed after stopping fluoxetine before starting an MAOI.
Concomitant use in patients taking pimozide is contraindicated (see PRECAUTIONS).
Thioridazine should not be administered with fluoxetine or within a minimum of 5 weeks after fluoxetine has been discontinued (see WARNINGS).
- Drug Information Provided by National Library of Medicine (NLM).